

Patricia A Jorquera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6277084/publications.pdf>

Version: 2024-02-01

20
papers

583
citations

623574

14
h-index

794469

19
g-index

20
all docs

20
docs citations

20
times ranked

1077
citing authors

#	ARTICLE	IF	CITATIONS
1	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015â€“2016. <i>Antiviral Research</i> , 2017, 146, 12-20.	1.9	87
2	Respiratory syncytial virus: prospects for new and emerging therapeutics. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 609-615.	1.0	58
3	Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains. <i>Viral Immunology</i> , 2012, 25, 120502120244005.	0.6	56
4	A Respiratory Syncytial Virus (RSV) Anti-G Protein F(abâ€²) ₂ Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice. <i>Journal of Virology</i> , 2013, 87, 10955-10967.	1.5	53
5	Prophylaxis with a Respiratory Syncytial Virus (RSV) Anti-G Protein Monoclonal Antibody Shifts the Adaptive Immune Response to RSV rA2-line19F Infection from Th2 to Th1 in BALB/c Mice. <i>Journal of Virology</i> , 2014, 88, 10569-10583.	1.5	48
6	Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease. <i>PLoS ONE</i> , 2013, 8, e74905.	1.1	46
7	Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. <i>Expert Review of Vaccines</i> , 2016, 15, 173-187.	2.0	37
8	Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. <i>Vaccines</i> , 2016, 4, 45.	2.1	27
9	Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication <i>In Vitro</i> . <i>Journal of Virology</i> , 2019, 93, .	1.5	27
10	Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. <i>Vaccine</i> , 2010, 28, 3238-3246.	1.7	25
11	Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease. <i>Vaccines</i> , 2015, 3, 829-849.	2.1	23
12	MicroRNA-555 has potent antiviral properties against poliovirus. <i>Journal of General Virology</i> , 2016, 97, 659-668.	1.3	21
13	A mucosal adjuvant for the inactivated poliovirus vaccine. <i>Vaccine</i> , 2014, 32, 558-563.	1.7	17
14	Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types. <i>Frontiers in Immunology</i> , 2019, 10, 2323.	2.2	15
15	Advances in and the potential of vaccines for respiratory syncytial virus. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 411-427.	1.0	14
16	Human Respiratory Syncytial Virus: An Introduction. <i>Methods in Molecular Biology</i> , 2016, 1442, 1-12.	0.4	12
17	Quantification of RSV Infectious Particles by Plaque Assay and Immunostaining Assay. <i>Methods in Molecular Biology</i> , 2016, 1442, 33-40.	0.4	7
18	Study of RNA-A Initiation Translation of The Infectious Pancreatic Necrosis Virus. <i>Virus Research</i> , 2017, 240, 121-129.	1.1	6

#	ARTICLE	IF	CITATIONS
19	MicroRNA Profiling from RSV-Infected Biofluids, Whole Blood, and Tissue Samples. <i>Methods in Molecular Biology</i> , 2016, 1442, 195-208.	0.4	4
20	Passive narcosis for anesthesia induction in cotton rats (<i>Sigmodon hispidus</i>). <i>Lab Animal</i> , 2016, 45, 333-337.	0.2	0